PedAM
Pediatric Disease Annotations & Medicines
| leukemia, acute lymphoblastic | ||||
| Disease ID | 1630 |
|---|---|
| Disease | leukemia, acute lymphoblastic |
| Definition | A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. |
| Synonym | acute lymphoblastic leukaemia, precursor-cell type acute lymphoblastic leukemia, precursor-cell type leukemia, acute lymphoid leukemia, lymphoblastic leukemia, lymphoid, acute lymphoblastic leukemia, acute lymphocytic leukemia, acute lymphoma, lymphoblastic precursor cell lymphoblastic leukaemia precursor cell lymphoblastic leukaemia, not phenotyped precursor cell lymphoblastic leukemia (morphologic abnormality) precursor cell lymphoblastic leukemia lymphoma precursor cell lymphoblastic leukemia, no icd-o subtype (morphologic abnormality) precursor cell lymphoblastic leukemia, not phenotyped precursor cell lymphoblastic leukemia-lymphoma precursor cell lymphoblastic leukemia-lymphoma [disease/finding] |
| OMIM | |
| UMLS | C1961102 |
| MeSH | |
| Curated Gene | Entrez_id | Symbol | Resource(Total Genes:41) ABCB1 | 5243 | CTD_human NQO1 | 1728 | CTD_human BCR | 613 | CTD_human TP53 | 7157 | CTD_human TCF3 | 6929 | CTD_human EPHX1 | 2052 | CTD_human CASP8 | 841 | CTD_human IDH1 | 3417 | CTD_human RUNX1 | 861 | CTD_human IKZF3 | 22806 | CTD_human CYP1B1 | 1545 | CTD_human ABL1 | 25 | CTD_human MTHFR | 4524 | CTD_human KMT2A | 4297 | CTD_human CDKN2A | 1029 | CTD_human;GWASCAT ARID5B | 84159 | CTD_human;GWASCAT CDK6 | 1021 | CTD_human MTRR | 4552 | CTD_human VPREB1 | 7441 | CTD_human ETV6 | 2120 | CTD_human RB1 | 5925 | CTD_human SLC19A1 | 6573 | CTD_human ARNT | 405 | CTD_human P2RY8 | 286530 | CTD_human GATA3 | 2625 | GWASCAT PAX5 | 5079 | CTD_human;UNIPROT NAT2 | 10 | CTD_human HOXD4 | 3233 | CTD_human NT5C2 | 22978 | CTD_human HCK | 3055 | CTD_human IKZF2 | 22807 | CTD_human IKZF1 | 10320 | CTD_human;GWASCAT PAG1 | 55824 | CTD_human XRCC1 | 7515 | CTD_human CYP2C8 | 1558 | CTD_human CYP1A2 | 1544 | CTD_human PIP4K2A | 5305 | GWASCAT CEBPE | 1053 | CTD_human;GWASCAT PRDM14 | 63978 | CTD_human HLF | 3131 | CTD_human CRLF2 | 64109 | CTD_human |
| Inferring Gene | Entrez_id | Symbol | Resource(Total Genes:113) 5243 | ABCB1 | infer 595 | CCND1 | infer 2322 | FLT3 | infer 3115 | HLA-DPB1 | infer 5551 | PRF1 | infer 7298 | TYMS | infer 10257 | ABCC4 | infer 80332 | ADAM33 | infer 154 | ADRB2 | infer 84159 | ARID5B | infer 940 | CD28 | infer 958 | CD40 | infer 941 | CD80 | infer 1029 | CDKN2A | infer 1030 | CDKN2B | infer 1053 | CEBPE | infer 1394 | CRHR1 | infer 55790 | CSGALNACT1 | infer 1493 | CTLA4 | infer 1543 | CYP1A1 | infer 1565 | CYP2D6 | infer 1571 | CYP2E1 | infer 1576 | CYP3A4 | infer 1577 | CYP3A5 | infer 1616 | DAXX | infer 780 | DDR1 | infer 1607 | DGKB | infer 1719 | DHFR | infer 9844 | ELMO1 | infer 2052 | EPHX1 | infer 2068 | ERCC2 | infer 2120 | ETV6 | infer 2212 | FCGR2A | infer 2625 | GATA3 | infer 8836 | GGH | infer 2944 | GSTM1 | infer 9446 | GSTO1 | infer 119391 | GSTO2 | infer 2950 | GSTP1 | infer 2952 | GSTT1 | infer 3105 | HLA-A | infer 3106 | HLA-B | infer 3123 | HLA-DRB1 | infer 10855 | HPSE | infer 8870 | IER3 | infer 3586 | IL10 | infer 3592 | IL12A | infer 3593 | IL12B | infer 3594 | IL12RB1 | infer 3595 | IL12RB2 | infer 3600 | IL15 | infer 3558 | IL2 | infer 3559 | IL2RA | infer 3565 | IL4 | infer 3566 | IL4R | infer 3569 | IL6 | infer 3617 | IMPG1 | infer 3704 | ITPA | infer 3716 | JAK1 | infer 3845 | KRAS | infer 92255 | LMBRD2 | infer 4049 | LTA | infer 84441 | MAML2 | infer 4193 | MDM2 | infer 4282 | MIF | infer 4311 | MME | infer 4353 | MPO | infer 2206 | MS4A2 | infer 4507 | MTAP | infer 4522 | MTHFD1 | infer 4524 | MTHFR | infer 4548 | MTR | infer 4552 | MTRR | infer 4595 | MUTYH | infer 10 | NAT2 | infer 8202 | NCOA3 | infer 4790 | NFKB1 | infer 4792 | NFKBIA | infer 4793 | NFKBIB | infer 4837 | NNMT | infer 50508 | NOX3 | infer 1728 | NQO1 | infer 2908 | NR3C1 | infer 4893 | NRAS | infer 4968 | OGG1 | infer 79476 | OR5AL2P | infer 51131 | PHF11 | infer 10196 | PRMT3 | infer 5743 | PTGS2 | infer 5781 | PTPN11 | infer 5795 | PTPRJ | infer 5981 | RFC1 | infer 646255 | RPL19P16 | infer 861 | RUNX1 | infer 6470 | SHMT1 | infer 6573 | SLC19A1 | infer 28232 | SLCO3A1 | infer 6644 | SRIP1 | infer 338596 | ST8SIA6 | infer 6774 | STAT3 | infer 6775 | STAT4 | infer 6776 | STAT5A | infer 6777 | STAT5B | infer 6778 | STAT6 | infer 7040 | TGFB1 | infer 7046 | TGFBR1 | infer 7048 | TGFBR2 | infer 7157 | TP53 | infer 8626 | TP63 | infer 7172 | TPMT | infer 7421 | VDR | infer 7498 | XDH | infer 7515 | XRCC1 | infer |
| Text Mined Gene | (Waiting for update.) |
| Locus | (Waiting for update.) |
| Disease ID | 1630 |
|---|---|
| Disease | leukemia, acute lymphoblastic |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | (Waiting for update.) |
| Disease ID | 1630 |
|---|---|
| Disease | leukemia, acute lymphoblastic |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | (Waiting for update.) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:146) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs1045642 | 12851703 | 5243 | ABCB1 | umls:C1961102 | BeFree | Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. | 0.159801061 | 2003 | ABCB1 | 7 | 87509329 | A | T,G |
| rs1045642 | 23244145 | 5243 | ABCB1 | umls:C1961102 | BeFree | Is the MDR1 C3435T polymorphism responsible for oral mucositis in children with acute lymphoblastic leukemia? | 0.159801061 | 2012 | ABCB1 | 7 | 87509329 | A | T,G |
| rs1045642 | 19317599 | 5243 | ABCB1 | umls:C1961102 | BeFree | MDR1 C3435T polymorphism in Mexican children with acute lymphoblastic leukemia and in healthy individuals. | 0.159801061 | 2008 | ABCB1 | 7 | 87509329 | A | T,G |
| rs104893636 | 15776434 | 3233 | HOXD4 | umls:C1961102 | BeFree | These comprised the germline c.242A>T (p.Glu81Val) missense mutation of HOXD4, detected in two children diagnosed with acute lymphoblastic leukemia (ALL). | 0.120271442 | 2005 | HOXD3;HOXD4 | 2 | 176151875 | A | C,T |
| rs10508343 | 19176441 | 2625 | GATA3 | umls:C1961102 | GAD | [Host genetic variations are associated with treatment response for childhood ALL, with polymorphisms related to leukemia cell biology and host drug disposition associated with lower risk of residual disease.] | 0.124734064 | 2009 | NA | 10 | 8108750 | C | A |
| rs10508343 | 19176441 | 79783 | SUGCT | umls:C1961102 | GAD | [Host genetic variations are associated with treatment response for childhood ALL, with polymorphisms related to leukemia cell biology and host drug disposition associated with lower risk of residual disease.] | 0.002367032 | 2009 | NA | 10 | 8108750 | C | A |
| rs1051266 | 22838948 | 2346 | FOLH1 | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.000271442 | 2012 | SLC19A1 | 21 | 45537880 | T | C |
| rs1051266 | 22838948 | 6470 | SHMT1 | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.00973957 | 2012 | SLC19A1 | 21 | 45537880 | T | C |
| rs1051266 | 18458567 | 6573 | SLC19A1 | umls:C1961102 | BeFree | We investigated preliminarily whether methylenetetrahydrofolate reductase (MTHFR) 677C/T or reduced folate carrier 1 (RFC1) 80G/A polymorphisms were associated with toxicities during maintenance chemotherapy with mercaptopurine (6MP) and methotrexate (MTX) in children with acute lymphoblastic leukemia or lymphoblastic lymphoma. | 0.132082858 | 2008 | SLC19A1 | 21 | 45537880 | T | C |
| rs1051266 | 22838948 | 4524 | MTHFR | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.232099662 | 2012 | SLC19A1 | 21 | 45537880 | T | C |
| rs1051266 | 18458567 | 4524 | MTHFR | umls:C1961102 | BeFree | We investigated preliminarily whether methylenetetrahydrofolate reductase (MTHFR) 677C/T or reduced folate carrier 1 (RFC1) 80G/A polymorphisms were associated with toxicities during maintenance chemotherapy with mercaptopurine (6MP) and methotrexate (MTX) in children with acute lymphoblastic leukemia or lymphoblastic lymphoma. | 0.232099662 | 2008 | SLC19A1 | 21 | 45537880 | T | C |
| rs1051266 | 22838948 | 7298 | TYMS | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.022007993 | 2012 | SLC19A1 | 21 | 45537880 | T | C |
| rs1051266 | 19020309 | 5981 | RFC1 | umls:C1961102 | GAD | [For the first time, we associate the RFC1 80G>A and NNMT IVS -151C>T variants to an increased ALL susceptibility.] | 0.015102394 | 2009 | SLC19A1 | 21 | 45537880 | T | C |
| rs1051266 | 22838948 | 6573 | SLC19A1 | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.132082858 | 2012 | SLC19A1 | 21 | 45537880 | T | C |
| rs1051266 | 22914600 | 6573 | SLC19A1 | umls:C1961102 | BeFree | This study evaluated the effect of the G80A polymorphism in the RFC1 gene on survival and risk of relapse of acute lymphoblastic leukemia. | 0.132082858 | 2012 | SLC19A1 | 21 | 45537880 | T | C |
| rs10821936 | 20054350 | 84159 | ARID5B | umls:C1961102 | GAD | [ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence.] | 0.247915422 | 2010 | ARID5B | 10 | 61963818 | C | T |
| rs10821936 | 24564228 | 1053 | CEBPE | umls:C1961102 | BeFree | The SNPs (IKZF1 rs11978267, ARID5B rs10821936 and rs10994982, CEBPE rs2239633) were genotyped in 265 cases [169 acute lymphoblastic leukemia (ALL) and 96 acute myeloid leukaemia (AML)] and 505 controls by Taqman allelic discrimination assay. | 0.243452799 | 2014 | ARID5B | 10 | 61963818 | C | T |
| rs10828317 | 23996088 | 5305 | PIP4K2A | umls:C1961102 | GWASCAT | Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. | 0.120271442 | 2014 | NA | NA | NA | NA | NA |
| rs10828317 | 23996088 | 861 | RUNX1 | umls:C1961102 | BeFree | The rs10828317 association was shown to be specifically associated with hyperdiploid ALL, whereas the rs3824662-associated risk was confined to nonhyperdiploid non-TEL-AML1 + ALL. | 0.19716252 | 2014 | NA | NA | NA | NA | NA |
| rs10994982 | 24564228 | 1053 | CEBPE | umls:C1961102 | BeFree | The SNPs (IKZF1 rs11978267, ARID5B rs10821936 and rs10994982, CEBPE rs2239633) were genotyped in 265 cases [169 acute lymphoblastic leukemia (ALL) and 96 acute myeloid leukaemia (AML)] and 505 controls by Taqman allelic discrimination assay. | 0.243452799 | 2014 | ARID5B | 10 | 61950345 | A | G |
| rs111033557 | 15863206 | 3077 | HFE | umls:C1961102 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.008630058 | 2005 | HFE | 6 | 26090939 | G | A |
| rs111033557 | 15863206 | 7036 | TFR2 | umls:C1961102 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.000271442 | 2005 | HFE | 6 | 26090939 | G | A |
| rs111033563 | 15863206 | 3077 | HFE | umls:C1961102 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.008630058 | 2005 | HFE | 6 | 26092916 | A | C |
| rs111033563 | 15863206 | 7036 | TFR2 | umls:C1961102 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.000271442 | 2005 | HFE | 6 | 26092916 | A | C |
| rs11978267 | 24564228 | 1053 | CEBPE | umls:C1961102 | BeFree | The SNPs (IKZF1 rs11978267, ARID5B rs10821936 and rs10994982, CEBPE rs2239633) were genotyped in 265 cases [169 acute lymphoblastic leukemia (ALL) and 96 acute myeloid leukaemia (AML)] and 505 controls by Taqman allelic discrimination assay. | 0.243452799 | 2014 | IKZF1;LOC105375275 | 7 | 50398606 | A | G |
| rs11980379 | 23996088 | 10320 | IKZF1 | umls:C1961102 | GWASCAT | Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. | 0.265946256 | 2014 | IKZF1 | 7 | 50402283 | T | C |
| rs12105972 | 20189245 | 6936 | GCFC2 | umls:C1961102 | GAD | [Genome-wide association study of childhood acute lymphoblastic leukemia in Korea.] | 0.002367032 | 2010 | NA | 2 | 76421434 | G | C |
| rs121913459 | 20471447 | 25 | ABL1 | umls:C1961102 | BeFree | This cell line may provide a useful model for in vitro and in vivo cellular and molecular studies of BCR-ABL-positive ALL with T315I mutation. | 0.184119871 | 2010 | ABL1 | 9 | 130872896 | C | T |
| rs121913459 | 16990603 | 25 | ABL1 | umls:C1961102 | BeFree | MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. | 0.184119871 | 2007 | ABL1 | 9 | 130872896 | C | T |
| rs121913459 | 22587422 | 25 | ABL1 | umls:C1961102 | BeFree | The BCR-ABL T315I kinase domain mutation is insensitive to dasatinib therapy for Philadelphia-positive acute lymphoid leukemia (Ph + ALL) patients. | 0.184119871 | 2012 | ABL1 | 9 | 130872896 | C | T |
| rs13181 | 18349268 | 2068 | ERCC2 | umls:C1961102 | BeFree | In this analysis, small associations of the XPD Lys 751 Gln polymorphism with cancer risk for esophageal cancer [for Lys/Gln versus Lys/Lys: odds ratio (OR), 1.34; 95% confidence interval (95% CI), 1.10-1.64; for Gln/Gln versus Lys/Lys: OR, 1.61; 95% CI, 1.16-2.25] and acute lymphoblastic leukemia (for Gln/Gln versus Lys/Lys: OR, 1.83; 95% CI, 1.21-2.75) are revealed. | 0.007915422 | 2008 | ERCC2;KLC3 | 19 | 45351661 | T | A,G |
| rs140422742 | 15462611 | 2908 | NR3C1 | umls:C1961102 | BeFree | Towards this aim we analyzed the CYP3A4-290A/G substitution and three NR3C1 polymorphisms (200G/A, 1220A/G and BclI RFLP) in 222 children with acute lymphoblastic leukemia (ALL) whose treatment protocols, among other components, contained corticosteroid drugs. | 0.00853425 | 2004 | CYP3A4 | 7 | 99778046 | T | C,G |
| rs140422742 | 15462611 | 1576 | CYP3A4 | umls:C1961102 | BeFree | Towards this aim we analyzed the CYP3A4-290A/G substitution and three NR3C1 polymorphisms (200G/A, 1220A/G and BclI RFLP) in 222 children with acute lymphoblastic leukemia (ALL) whose treatment protocols, among other components, contained corticosteroid drugs. | 0.003724241 | 2004 | CYP3A4 | 7 | 99778046 | T | C,G |
| rs146519482 | 15863206 | 3077 | HFE | umls:C1961102 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.008630058 | 2005 | HFE | 6 | 26091475 | G | C,T |
| rs146519482 | 15863206 | 7036 | TFR2 | umls:C1961102 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.000271442 | 2005 | HFE | 6 | 26091475 | G | C,T |
| rs1569175 | 19176441 | 79568 | C2orf47 | umls:C1961102 | GAD | [Host genetic variations are associated with treatment response for childhood ALL, with polymorphisms related to leukemia cell biology and host drug disposition associated with lower risk of residual disease.] | 0.002367032 | 2009 | LOC105373834 | 2 | 200157231 | T | C |
| rs1695 | 19256768 | 2950 | GSTP1 | umls:C1961102 | BeFree | Role of GSTM1 (Present/Null) and GSTP1 (Ile105Val) polymorphisms in susceptibility to acute lymphoblastic leukemia among the South Indian population. | 0.038477528 | 2008 | GSTP1 | 11 | 67585218 | A | G |
| rs1695 | 19256768 | 2944 | GSTM1 | umls:C1961102 | BeFree | Role of GSTM1 (Present/Null) and GSTP1 (Ile105Val) polymorphisms in susceptibility to acute lymphoblastic leukemia among the South Indian population. | 0.0537793 | 2008 | GSTP1 | 11 | 67585218 | A | G |
| rs17007695 | 19176441 | 3600 | IL15 | umls:C1961102 | GAD | [Host genetic variations are associated with treatment response for childhood ALL, with polymorphisms related to leukemia cell biology and host drug disposition associated with lower risk of residual disease.] | 0.008001298 | 2009 | NA | 4 | 141788570 | T | C |
| rs17433222 | 20438785 | 714 | C1QC | umls:C1961102 | GAD | [Polymorphisms in innate immunity genes and risk of childhood leukemia.] | 0.002367032 | 2010 | C1QB | 1 | 22652153 | G | A |
| rs17505102 | 22076464 | 8626 | TP63 | umls:C1961102 | GAD | [Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia.] | 0.002367032 | 2012 | TP63 | 3 | 189683987 | G | C |
| rs1799945 | 15863206 | 7036 | TFR2 | umls:C1961102 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.000271442 | 2005 | HFE | 6 | 26090951 | C | G |
| rs1799945 | 15863206 | 3077 | HFE | umls:C1961102 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.008630058 | 2005 | HFE | 6 | 26090951 | C | G |
| rs1800562 | 15863206 | 7036 | TFR2 | umls:C1961102 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.000271442 | 2005 | HFE | 6 | 26092913 | G | A |
| rs1800562 | 15863206 | 3077 | HFE | umls:C1961102 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.008630058 | 2005 | HFE | 6 | 26092913 | G | A |
| rs1801131 | 23652803 | 4524 | MTHFR | umls:C1961102 | BeFree | Multiple Cox regression analyses revealed an association of minimal residual disease (hazard ratio 7.3; P < .001) and methylenetetrahydrofolate reductase rs1801131 (hazard ratio 3.1; P = .015) with event-free survival in the ALL-BFM 2000 study population. | 0.232099662 | 2013 | MTHFR | 1 | 11794419 | T | G |
| rs1801394 | 19020309 | 4552 | MTRR | umls:C1961102 | GAD | [Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia.] | 0.130011012 | 2009 | MTRR;FASTKD3 | 5 | 7870860 | A | G |
| rs1801394 | 24261678 | 4552 | MTRR | umls:C1961102 | BeFree | This meta-analysis suggests that MTRR A66G GG is associated with decreased risk of leukemia in a Caucasian population and in children, especially for ALL. | 0.130011012 | 2015 | MTRR;FASTKD3 | 5 | 7870860 | A | G |
| rs1805087 | 21643952 | 4548 | MTR | umls:C1961102 | BeFree | In order to determine the influence of polymorphism in thymidylate synthase (TS 28-bp repeat) and methionine synthase (MS A2756G) genes on the susceptibility to acute lymphoblastic leukemia (ALL), 73 children with ALL and 128 age and sex matched unrelated healthy individuals from the Kermanshah Province of Iran were screened. | 0.010282454 | 2012 | MTR | 1 | 236885200 | A | G |
| rs1805087 | 21643952 | 7298 | TYMS | umls:C1961102 | BeFree | In order to determine the influence of polymorphism in thymidylate synthase (TS 28-bp repeat) and methionine synthase (MS A2756G) genes on the susceptibility to acute lymphoblastic leukemia (ALL), 73 children with ALL and 128 age and sex matched unrelated healthy individuals from the Kermanshah Province of Iran were screened. | 0.022007993 | 2012 | MTR | 1 | 236885200 | A | G |
| rs1805087 | 19020309 | 4548 | MTR | umls:C1961102 | GAD | [Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia.] | 0.010282454 | 2009 | MTR | 1 | 236885200 | A | G |
| rs1966862 | 20670164 | 83478 | ARHGAP24 | umls:C1961102 | BeFree | This study suggested rs1966862 (ARHGAP24) and the other SNPs to be predictive factors for drug-induced hepatotoxicity during the maintenance phase in pediatric patients with ALL or LBL. | 0.003995683 | 2010 | ARHGAP24 | 4 | 85766908 | A | G |
| rs1979277 | 22838948 | 6573 | SLC19A1 | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.132082858 | 2012 | SHMT1 | 17 | 18328782 | G | A |
| rs1979277 | 19020309 | 6470 | SHMT1 | umls:C1961102 | GAD | [Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia.] | 0.00973957 | 2009 | SHMT1 | 17 | 18328782 | G | A |
| rs1979277 | 22838948 | 4524 | MTHFR | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.232099662 | 2012 | SHMT1 | 17 | 18328782 | G | A |
| rs1979277 | 22838948 | 7298 | TYMS | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.022007993 | 2012 | SHMT1 | 17 | 18328782 | G | A |
| rs1979277 | 22838948 | 2346 | FOLH1 | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.000271442 | 2012 | SHMT1 | 17 | 18328782 | G | A |
| rs1979277 | 22838948 | 6470 | SHMT1 | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.00973957 | 2012 | SHMT1 | 17 | 18328782 | G | A |
| rs2032582 | 24142546 | 5243 | ABCB1 | umls:C1961102 | BeFree | In the subgroup analysis, according to the type of leukemia, significant association was found between MDR1 G2677T polymorphism and myeloid leukemia but not lymphoblastic leukemia (TT vs. GG: OR = 0.66, 95% CI = 0.46-0.95, P = 0.026; TT vs. | 0.159801061 | 2013 | ABCB1 | 7 | 87531302 | A | T,C |
| rs207954 | 22076464 | 28232 | SLCO3A1 | umls:C1961102 | GAD | [Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia.] | 0.002367032 | 2012 | SLCO3A1 | 15 | 92114143 | T | C |
| rs2236225 | 19020309 | 4522 | MTHFD1 | umls:C1961102 | GAD | [Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia.] | 0.007372538 | 2009 | MTHFD1 | 14 | 64442127 | G | A |
| rs2239633 | 23996088 | 1053 | CEBPE | umls:C1961102 | GWASCAT | Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. | 0.243452799 | 2014 | CEBPE | 14 | 23119848 | G | A |
| rs2239633 | 25195121 | 1053 | CEBPE | umls:C1961102 | BeFree | The CEBPE rs2239633 polymorphism increased B cell ALL risk (OR = 1.29, 95 % CI 1.15-1.44, P < 0.01) and B hyperdiploid ALL risk (OR = 1.84, 95 % CI 1.40-2.43, P < 0.01). | 0.243452799 | 2014 | CEBPE | 14 | 23119848 | G | A |
| rs2239633 | 24564228 | 1053 | CEBPE | umls:C1961102 | BeFree | The SNPs (IKZF1 rs11978267, ARID5B rs10821936 and rs10994982, CEBPE rs2239633) were genotyped in 265 cases [169 acute lymphoblastic leukemia (ALL) and 96 acute myeloid leukaemia (AML)] and 505 controls by Taqman allelic discrimination assay. | 0.243452799 | 2014 | CEBPE | 14 | 23119848 | G | A |
| rs2536 | 21973240 | 2475 | MTOR | umls:C1961102 | BeFree | We observed that the variant genotype TC of mTOR rs2536 was associated with a significantly decreased risk of childhood ALL (adjusted odds ratio [OR] = 0.67, 95% confidence interval [CI] = 0.46-0.96), and the association was more pronounced in high-risk ALL and T-phenotype ALL groups. | 0.000271442 | 2012 | MTOR | 1 | 11106656 | T | C |
| rs267607131 | 10077164 | 7150 | TOP1 | umls:C1961102 | BeFree | In previous studies, we isolated a mutant DNA topoisomerase I cDNA from a camptothecin (CPT)-resistant human T-lymphoblastic leukemia cell line, CPT-K5, and demonstrated that an amino acid change from Asp to Gly at residue 533 is responsible for the CPT resistance of the enzyme. | 0.000271442 | 1999 | TOP1;PLCG1-AS1 | 20 | 41114115 | A | G |
| rs267759 | 19176441 | 92255 | LMBRD2 | umls:C1961102 | GAD | [Host genetic variations are associated with treatment response for childhood ALL, with polymorphisms related to leukemia cell biology and host drug disposition associated with lower risk of residual disease.] | 0.002367032 | 2009 | LMBRD2 | 5 | 36137518 | A | G |
| rs28934595 | 15863206 | 3077 | HFE | umls:C1961102 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.008630058 | 2005 | HFE | 6 | 26091354 | A | C |
| rs28934595 | 15863206 | 7036 | TFR2 | umls:C1961102 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.000271442 | 2005 | HFE | 6 | 26091354 | A | C |
| rs28934889 | 15863206 | 7036 | TFR2 | umls:C1961102 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.000271442 | 2005 | HFE | 6 | 26090921 | G | A |
| rs28934889 | 15863206 | 3077 | HFE | umls:C1961102 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.008630058 | 2005 | HFE | 6 | 26090921 | G | A |
| rs35229355 | 19176441 | 50508 | NOX3 | umls:C1961102 | GAD | [Host genetic variations are associated with treatment response for childhood ALL, with polymorphisms related to leukemia cell biology and host drug disposition associated with lower risk of residual disease.] | 0.002367032 | 2009 | NA | 6 | 155608667 | C | T |
| rs359312 | 19176441 | 338596 | ST8SIA6 | umls:C1961102 | GAD | [Host genetic variations are associated with treatment response for childhood ALL, with polymorphisms related to leukemia cell biology and host drug disposition associated with lower risk of residual disease.] | 0.002367032 | 2009 | ST8SIA6 | 10 | 17346144 | C | T |
| rs35947132 | 15921391 | 5551 | PRF1 | umls:C1961102 | BeFree | We screened 100 children with acute lymphoblastic leukemia (ALL) to assess the incidence of single amino acid change A91V in perforin. | 0.008001298 | 2005 | PRF1 | 10 | 70600631 | G | A |
| rs368005287 | 15462611 | 2908 | NR3C1 | umls:C1961102 | BeFree | Towards this aim we analyzed the CYP3A4-290A/G substitution and three NR3C1 polymorphisms (200G/A, 1220A/G and BclI RFLP) in 222 children with acute lymphoblastic leukemia (ALL) whose treatment protocols, among other components, contained corticosteroid drugs. | 0.00853425 | 2004 | CYP3A4 | 7 | 99762071 | C | T |
| rs368005287 | 15462611 | 1576 | CYP3A4 | umls:C1961102 | BeFree | Towards this aim we analyzed the CYP3A4-290A/G substitution and three NR3C1 polymorphisms (200G/A, 1220A/G and BclI RFLP) in 222 children with acute lymphoblastic leukemia (ALL) whose treatment protocols, among other components, contained corticosteroid drugs. | 0.003724241 | 2004 | CYP3A4 | 7 | 99762071 | C | T |
| rs368087026 | 22838948 | 4524 | MTHFR | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.232099662 | 2012 | SLC19A1 | 21 | 45530890 | G | A |
| rs368087026 | 22838948 | 2346 | FOLH1 | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.000271442 | 2012 | SLC19A1 | 21 | 45530890 | G | A |
| rs368087026 | 18458567 | 6573 | SLC19A1 | umls:C1961102 | BeFree | We investigated preliminarily whether methylenetetrahydrofolate reductase (MTHFR) 677C/T or reduced folate carrier 1 (RFC1) 80G/A polymorphisms were associated with toxicities during maintenance chemotherapy with mercaptopurine (6MP) and methotrexate (MTX) in children with acute lymphoblastic leukemia or lymphoblastic lymphoma. | 0.132082858 | 2008 | SLC19A1 | 21 | 45530890 | G | A |
| rs368087026 | 18458567 | 4524 | MTHFR | umls:C1961102 | BeFree | We investigated preliminarily whether methylenetetrahydrofolate reductase (MTHFR) 677C/T or reduced folate carrier 1 (RFC1) 80G/A polymorphisms were associated with toxicities during maintenance chemotherapy with mercaptopurine (6MP) and methotrexate (MTX) in children with acute lymphoblastic leukemia or lymphoblastic lymphoma. | 0.232099662 | 2008 | SLC19A1 | 21 | 45530890 | G | A |
| rs368087026 | 22838948 | 6470 | SHMT1 | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.00973957 | 2012 | SLC19A1 | 21 | 45530890 | G | A |
| rs368087026 | 22838948 | 6573 | SLC19A1 | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.132082858 | 2012 | SLC19A1 | 21 | 45530890 | G | A |
| rs368087026 | 22838948 | 7298 | TYMS | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.022007993 | 2012 | SLC19A1 | 21 | 45530890 | G | A |
| rs368939818 | 22838948 | 6573 | SLC19A1 | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.132082858 | 2012 | FOLH1 | 11 | 49156734 | G | A |
| rs368939818 | 22838948 | 7298 | TYMS | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.022007993 | 2012 | FOLH1 | 11 | 49156734 | G | A |
| rs368939818 | 22838948 | 2346 | FOLH1 | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.000271442 | 2012 | FOLH1 | 11 | 49156734 | G | A |
| rs368939818 | 22838948 | 4524 | MTHFR | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.232099662 | 2012 | FOLH1 | 11 | 49156734 | G | A |
| rs368939818 | 22838948 | 6470 | SHMT1 | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.00973957 | 2012 | FOLH1 | 11 | 49156734 | G | A |
| rs3731217 | 20453839 | 1029 | CDKN2A | umls:C1961102 | BeFree | Using data from a genome-wide association study of 907 individuals with childhood acute lymphoblastic leukemia (cases) and 2,398 controls and with validation in samples totaling 2,386 cases and 2,419 controls, we have shown that common variation at 9p21.3 (rs3731217, intron 1 of CDKN2A) influences acute lymphoblastic leukemia risk (odds ratio = 0.71, P = 3.01 x 10(-11)), irrespective of cell lineage. | 0.274751948 | 2010 | CDKN2A | 9 | 21984662 | A | C |
| rs3731217 | 23996088 | 1029 | CDKN2A | umls:C1961102 | GWASCAT | Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. | 0.274751948 | 2014 | CDKN2A | 9 | 21984662 | A | C |
| rs3776932 | 20189245 | 4124 | MAN2A1 | umls:C1961102 | GAD | [Genome-wide association study of childhood acute lymphoblastic leukemia in Korea.] | 0.002367032 | 2010 | MAN2A1 | 5 | 109850287 | T | G |
| rs3794845 | 20438785 | 4155 | MBP | umls:C1961102 | GAD | [Subgroup analysis showed that Ly96 rs78380171 and MBP rs3794845 were significantly associated with the risk of acute lymphoblastic leukemia (p(trend) < 0.001).] | 0.002638474 | 2010 | MBP | 18 | 77002561 | G | C |
| rs3794845 | 20438785 | 4155 | MBP | umls:C1961102 | BeFree | Subgroup analysis showed that Ly96 rs78380171 and MBP rs3794845 were significantly associated with the risk of acute lymphoblastic leukemia (p(trend) < 0.001). | 0.002638474 | 2010 | MBP | 18 | 77002561 | G | C |
| rs3824662 | 25468567 | 2625 | GATA3 | umls:C1961102 | GWASCAT | A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. | 0.124734064 | 2015 | GATA3 | 10 | 8062245 | C | A |
| rs3824662 | 23996088 | 2625 | GATA3 | umls:C1961102 | GWASCAT | Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. | 0.124734064 | 2014 | GATA3 | 10 | 8062245 | C | A |
| rs3824662 | 23996088 | 861 | RUNX1 | umls:C1961102 | BeFree | The rs10828317 association was shown to be specifically associated with hyperdiploid ALL, whereas the rs3824662-associated risk was confined to nonhyperdiploid non-TEL-AML1 + ALL. | 0.19716252 | 2014 | GATA3 | 10 | 8062245 | C | A |
| rs386514057 | 22838948 | 2346 | FOLH1 | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.000271442 | 2012 | NA | NA | NA | NA | NA |
| rs386514057 | 22838948 | 6573 | SLC19A1 | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.132082858 | 2012 | NA | NA | NA | NA | NA |
| rs386514057 | 22838948 | 6470 | SHMT1 | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.00973957 | 2012 | NA | NA | NA | NA | NA |
| rs386514057 | 22914600 | 6573 | SLC19A1 | umls:C1961102 | BeFree | This study evaluated the effect of the G80A polymorphism in the RFC1 gene on survival and risk of relapse of acute lymphoblastic leukemia. | 0.132082858 | 2012 | NA | NA | NA | NA | NA |
| rs386514057 | 18458567 | 4524 | MTHFR | umls:C1961102 | BeFree | We investigated preliminarily whether methylenetetrahydrofolate reductase (MTHFR) 677C/T or reduced folate carrier 1 (RFC1) 80G/A polymorphisms were associated with toxicities during maintenance chemotherapy with mercaptopurine (6MP) and methotrexate (MTX) in children with acute lymphoblastic leukemia or lymphoblastic lymphoma. | 0.232099662 | 2008 | NA | NA | NA | NA | NA |
| rs386514057 | 22838948 | 7298 | TYMS | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.022007993 | 2012 | NA | NA | NA | NA | NA |
| rs386514057 | 18458567 | 6573 | SLC19A1 | umls:C1961102 | BeFree | We investigated preliminarily whether methylenetetrahydrofolate reductase (MTHFR) 677C/T or reduced folate carrier 1 (RFC1) 80G/A polymorphisms were associated with toxicities during maintenance chemotherapy with mercaptopurine (6MP) and methotrexate (MTX) in children with acute lymphoblastic leukemia or lymphoblastic lymphoma. | 0.132082858 | 2008 | NA | NA | NA | NA | NA |
| rs386514057 | 22838948 | 4524 | MTHFR | umls:C1961102 | BeFree | Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques. | 0.232099662 | 2012 | NA | NA | NA | NA | NA |
| rs386626619 | 20538800 | 3418 | IDH2 | umls:C1961102 | BeFree | Moreover, we identified IDH mutations in 2 JAK2 V617F myeloproliferative neoplasias (n = 96), a single case of acute lymphoblastic leukemia (n = 96), and none in chronic myeloid leukemias (n = 81). | 0.001085767 | 2010 | NA | NA | NA | NA | NA |
| rs386626619 | 20538800 | 3717 | JAK2 | umls:C1961102 | BeFree | Moreover, we identified IDH mutations in 2 JAK2 V617F myeloproliferative neoplasias (n = 96), a single case of acute lymphoblastic leukemia (n = 96), and none in chronic myeloid leukemias (n = 81). | 0.014439958 | 2010 | NA | NA | NA | NA | NA |
| rs386626619 | 20538800 | 3417 | IDH1 | umls:C1961102 | BeFree | Moreover, we identified IDH mutations in 2 JAK2 V617F myeloproliferative neoplasias (n = 96), a single case of acute lymphoblastic leukemia (n = 96), and none in chronic myeloid leukemias (n = 81). | 0.121085767 | 2010 | NA | NA | NA | NA | NA |
| rs3942852 | 22076464 | 5795 | PTPRJ | umls:C1961102 | GAD | [Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia.] | 0.002367032 | 2012 | PTPRJ | 11 | 48093537 | C | T |
| rs397507444 | 24237708 | 4524 | MTHFR | umls:C1961102 | BeFree | The effect of RFC G80A polymorphism in Cretan children with acute lymphoblastic leukemia and its interaction with MTHFR C677T and A1298C polymorphisms. | 0.232099662 | 2013 | MTHFR | 1 | 11794407 | T | G |
| rs397507444 | 17023046 | 1728 | NQO1 | umls:C1961102 | BeFree | Most studies found a strong association between the polymorphisms MTHFR, C677T or A1298C, and NQO1*2 or *3 and the risk of acute lymphoblastic leukemia (ALL). | 0.159391542 | 2006 | MTHFR | 1 | 11794407 | T | G |
| rs397507444 | 18804702 | 4524 | MTHFR | umls:C1961102 | BeFree | Certain common polymorphisms within the MTHFR gene (C677T, A1298C) result in reduced enzymatic activity and have been associated with reduced risk for a variety of cancers such as acute lymphocytic leukemia, lung and colorectal cancer. | 0.232099662 | 2008 | MTHFR | 1 | 11794407 | T | G |
| rs397507444 | 22017305 | 4524 | MTHFR | umls:C1961102 | BeFree | The aim of the present study was to determine the role of the two most common polymorphisms of the 5, 10-methylenetetrahydrofolate reductase (MTHFR) gene, MTHFR C677T and A1298C, and their interaction on the susceptibility to ALL. | 0.232099662 | 2012 | MTHFR | 1 | 11794407 | T | G |
| rs397507444 | 21495160 | 4524 | MTHFR | umls:C1961102 | BeFree | A meta-analysis of MTHFR C677T and A1298C polymorphisms and risk of acute lymphoblastic leukemia in children. | 0.232099662 | 2012 | MTHFR | 1 | 11794407 | T | G |
| rs397507444 | 20367562 | 4524 | MTHFR | umls:C1961102 | BeFree | We conducted a case-control study in 95 north Indian children with acute lymphoblastic leukemia (ALL) and 255 controls, to investigate the role of MTHFR C677T and A1298C polymorphisms as risk factors in the development of ALL. | 0.232099662 | 2010 | MTHFR | 1 | 11794407 | T | G |
| rs397507444 | 17023046 | 4524 | MTHFR | umls:C1961102 | BeFree | Most studies found a strong association between the polymorphisms MTHFR, C677T or A1298C, and NQO1*2 or *3 and the risk of acute lymphoblastic leukemia (ALL). | 0.232099662 | 2006 | MTHFR | 1 | 11794407 | T | G |
| rs397507444 | 19391036 | 4524 | MTHFR | umls:C1961102 | BeFree | Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. | 0.232099662 | 2009 | MTHFR | 1 | 11794407 | T | G |
| rs397507520 | 22315187 | 5781 | PTPN11 | umls:C1961102 | BeFree | Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D. | 0.008815624 | 2012 | PTPN11 | 12 | 112453279 | G | C,T |
| rs4132601 | 24597983 | 10320 | IKZF1 | umls:C1961102 | BeFree | Since recently conducted genome-wide association (GWA) studies revealed that the common low-penetrance susceptibility allele at 7p12.2 (IKZF1 gene) confers an increased risk of pediatric ALL, we investigated whether the risk allele at rs4132601 also coexists with well-established prognostic factors, among 508 Polish pediatric patients with newly diagnosed ALL. | 0.265946256 | 2015 | IKZF1 | 7 | 50402906 | T | G |
| rs414580 | 24604828 | 10848 | PPP1R13L | umls:C1961102 | BeFree | Common variations rs6966 (3' UTR of PPP1R13L, chr 19q13.32, P = 4.55 × 10(-9)) and rs414580 (intron 2 of MSR1, chr 8p22, P = 6.09 × 10(-8)) were significantly associated with ALL. | 0.000271442 | 2014 | MSR1 | 8 | 16177793 | T | C,A |
| rs414580 | 24604828 | 4481 | MSR1 | umls:C1961102 | BeFree | Common variations rs6966 (3' UTR of PPP1R13L, chr 19q13.32, P = 4.55 × 10(-9)) and rs414580 (intron 2 of MSR1, chr 8p22, P = 6.09 × 10(-8)) were significantly associated with ALL. | 0.000271442 | 2014 | MSR1 | 8 | 16177793 | T | C,A |
| rs4149056 | 23233662 | 10599 | SLCO1B1 | umls:C1961102 | BeFree | This replicates findings using different schedules of high-dose methotrexate in St Jude ALL treatment protocols; a combined meta-analysis yields a P value of 5.7 x 10(-19) for the association of methotrexate clearance with SLCO1B1 SNP rs4149056. | 0.002638474 | 2013 | SLCO1B1 | 12 | 21178615 | T | C |
| rs45445694 | 19020309 | 7298 | TYMS | umls:C1961102 | GAD | [Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia.] | 0.022007993 | 2009 | NA | NA | NA | NA | NA |
| rs4723619 | 19176441 | 9844 | ELMO1 | umls:C1961102 | GAD | [Host genetic variations are associated with treatment response for childhood ALL, with polymorphisms related to leukemia cell biology and host drug disposition associated with lower risk of residual disease.] | 0.002367032 | 2009 | ELMO1 | 7 | 37226747 | T | C |
| rs6021191 | 25987655 | 4773 | NFATC2 | umls:C1961102 | BeFree | RNA-seq data available from 65 SJCRH ALL tumor samples and 52 Yoruba HapMap samples showed that samples carrying the rs6021191 variant had higher NFATC2 expression compared with noncarriers (P = 1.1 × 10(-3) and 0.03, respectively). | 0.000271442 | 2015 | NFATC2 | 20 | 51419700 | A | T |
| rs6125048 | 19176441 | 8202 | NCOA3 | umls:C1961102 | GAD | [Host genetic variations are associated with treatment response for childhood ALL, with polymorphisms related to leukemia cell biology and host drug disposition associated with lower risk of residual disease.] | 0.002367032 | 2009 | NCOA3 | 20 | 47579861 | G | T |
| rs6140264 | 20189245 | 54363 | HAO1 | umls:C1961102 | GAD | [Genome-wide association study of childhood acute lymphoblastic leukemia in Korea.] | 0.002367032 | 2010 | NA | 20 | 7395707 | G | A |
| rs61754966 | 15338273 | 4683 | NBN | umls:C1961102 | BeFree | Four children with acute lymphoblastic leukemia have been reported to be heterozygous for a germline and/or somatic missense mutation in NBS1, leading to the I171V substitution. | 0.003538676 | 2004 | NBN | 8 | 89978293 | T | C |
| rs694539 | 19020309 | 4837 | NNMT | umls:C1961102 | GAD | [For the first time, we associate the RFC1 80G>A and NNMT IVS -151C>T variants to an increased ALL susceptibility.] | 0.002638474 | 2009 | NA | 11 | 114262697 | C | T |
| rs6966 | 24604828 | 10848 | PPP1R13L | umls:C1961102 | BeFree | Common variations rs6966 (3' UTR of PPP1R13L, chr 19q13.32, P = 4.55 × 10(-9)) and rs414580 (intron 2 of MSR1, chr 8p22, P = 6.09 × 10(-8)) were significantly associated with ALL. | 0.000271442 | 2014 | PPP1R13L | 19 | 45379704 | T | A |
| rs6966 | 24604828 | 4481 | MSR1 | umls:C1961102 | BeFree | Common variations rs6966 (3' UTR of PPP1R13L, chr 19q13.32, P = 4.55 × 10(-9)) and rs414580 (intron 2 of MSR1, chr 8p22, P = 6.09 × 10(-8)) were significantly associated with ALL. | 0.000271442 | 2014 | PPP1R13L | 19 | 45379704 | T | A |
| rs6971925 | 19176441 | 1607 | DGKB | umls:C1961102 | GAD | [Host genetic variations are associated with treatment response for childhood ALL, with polymorphisms related to leukemia cell biology and host drug disposition associated with lower risk of residual disease.] | 0.002367032 | 2009 | DGKB | 7 | 14406292 | T | C |
| rs703817 | 20438785 | 6778 | STAT6 | umls:C1961102 | GAD | [Polymorphisms in innate immunity genes and risk of childhood leukemia.] | 0.004734064 | 2010 | STAT6 | 12 | 57096045 | C | T |
| rs7090445 | 23996088 | 84159 | ARID5B | umls:C1961102 | GWASCAT | Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. | 0.247915422 | 2014 | ARID5B | 10 | 61961417 | C | T |
| rs7115578 | 19176441 | 84441 | MAML2 | umls:C1961102 | GAD | [Host genetic variations are associated with treatment response for childhood ALL, with polymorphisms related to leukemia cell biology and host drug disposition associated with lower risk of residual disease.] | 0.002367032 | 2009 | MAML2 | 11 | 96266936 | G | A |
| rs7128311 | 19176441 | 10196 | PRMT3 | umls:C1961102 | GAD | [Host genetic variations are associated with treatment response for childhood ALL, with polymorphisms related to leukemia cell biology and host drug disposition associated with lower risk of residual disease.] | 0.002367032 | 2009 | NA | 11 | 20540973 | C | T |
| rs7156960 | 22076464 | 55668 | GPATCH2L | umls:C1961102 | GAD | [Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia.] | 0.002367032 | 2012 | NA | 14 | 76237008 | C | G |
| rs72481843 | 15462611 | 1576 | CYP3A4 | umls:C1961102 | BeFree | Towards this aim we analyzed the CYP3A4-290A/G substitution and three NR3C1 polymorphisms (200G/A, 1220A/G and BclI RFLP) in 222 children with acute lymphoblastic leukemia (ALL) whose treatment protocols, among other components, contained corticosteroid drugs. | 0.003724241 | 2004 | NR3C1 | 5 | 143300685 | C | G |
| rs72481843 | 15462611 | 2908 | NR3C1 | umls:C1961102 | BeFree | Towards this aim we analyzed the CYP3A4-290A/G substitution and three NR3C1 polymorphisms (200G/A, 1220A/G and BclI RFLP) in 222 children with acute lymphoblastic leukemia (ALL) whose treatment protocols, among other components, contained corticosteroid drugs. | 0.00853425 | 2004 | NR3C1 | 5 | 143300685 | C | G |
| rs77375493 | 20538800 | 3417 | IDH1 | umls:C1961102 | BeFree | Moreover, we identified IDH mutations in 2 JAK2 V617F myeloproliferative neoplasias (n = 96), a single case of acute lymphoblastic leukemia (n = 96), and none in chronic myeloid leukemias (n = 81). | 0.121085767 | 2010 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 20538800 | 3418 | IDH2 | umls:C1961102 | BeFree | Moreover, we identified IDH mutations in 2 JAK2 V617F myeloproliferative neoplasias (n = 96), a single case of acute lymphoblastic leukemia (n = 96), and none in chronic myeloid leukemias (n = 81). | 0.001085767 | 2010 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 20538800 | 3717 | JAK2 | umls:C1961102 | BeFree | Moreover, we identified IDH mutations in 2 JAK2 V617F myeloproliferative neoplasias (n = 96), a single case of acute lymphoblastic leukemia (n = 96), and none in chronic myeloid leukemias (n = 81). | 0.014439958 | 2010 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs7738636 | 22076464 | 3617 | IMPG1 | umls:C1961102 | GAD | [Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia.] | 0.002367032 | 2012 | LOC105377862 | 6 | 77080091 | A | C |
| rs78380171 | 20438785 | 4155 | MBP | umls:C1961102 | BeFree | Subgroup analysis showed that Ly96 rs78380171 and MBP rs3794845 were significantly associated with the risk of acute lymphoblastic leukemia (p(trend) < 0.001). | 0.002638474 | 2010 | LOC101927518 | 3 | 86720838 | A | G |
| rs80338880 | 15863206 | 3077 | HFE | umls:C1961102 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.008630058 | 2005 | TFR2;LOC105375428 | 7 | 100633100 | G | C |
| rs80338880 | 15863206 | 7036 | TFR2 | umls:C1961102 | BeFree | We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C). | 0.000271442 | 2005 | TFR2;LOC105375428 | 7 | 100633100 | G | C |
| rs920590 | 22076464 | 55790 | CSGALNACT1 | umls:C1961102 | GAD | [Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia.] | 0.002367032 | 2012 | NA | 8 | 19793650 | T | C |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:26) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C1961102 | allopurinol | D000493 | 315-30-0 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 6936839 | ||
| C1961102 | amsacrine | D000677 | - | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 1873770 | ||
| C1961102 | arsenic trioxide | C006632 | 1327-53-3 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 19781537 | ||
| C1961102 | busulfan | D002066 | 55-98-1 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 11069031 | ||
| C1961102 | carmustine | D002330 | 154-93-8 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 17264526 | ||
| C1961102 | chloramphenicol | D002701 | 56-75-7 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | marker/mechanism | 6071896 | ||
| C1961102 | clofarabine | C068329 | 123318-82-1 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 20057324 | ||
| C1961102 | cyclophosphamide | D003520 | 50-18-0 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 10457124 | ||
| C1961102 | cyclosporine | D016572 | 59865-13-3 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 17264526 | ||
| C1961102 | decitabine | C014347 | 2353-33-5 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 14604977 | ||
| C1961102 | leucovorin | D002955 | 1958/5/9 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 1519928 | ||
| C1961102 | imatinib mesylate | D000068877 | - | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 12476293 | ||
| C1961102 | melphalan | D008558 | 148-82-3 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 17264526 | ||
| C1961102 | methotrexate | D008727 | 1959/5/2 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 10457124 | ||
| C1961102 | mitoxantrone | D008942 | 65271-80-9 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 2214347 | ||
| C1961102 | paclitaxel | D017239 | - | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 19781537 | ||
| C1961102 | panobinostat | C496932 | - | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 23681230 | ||
| C1961102 | pegaspargase | C042705 | - | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 17356399 | ||
| C1961102 | sirolimus | D020123 | 53123-88-9 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 21898527 | ||
| C1961102 | temsirolimus | C401859 | - | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 16195324 | ||
| C1961102 | teniposide | D013713 | 29767-20-2 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 3111251 | ||
| C1961102 | thalidomide | D013792 | 50-35-1 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 17031469 | ||
| C1961102 | tretinoin | D014212 | 302-79-4 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 8695172 | ||
| C1961102 | troglitazone | C057693 | 97322-87-7 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 16809887 | ||
| C1961102 | vincristine | D014750 | - | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 10457124 | ||
| C1961102 | vindesine | D014751 | 53643-48-4 | precursor cell lymphoblastic leukemia-lymphoma | MESH:D054198 | therapeutic | 19428104 | ||
FDA approved drug and dosage information(Total Drugs:0) | |
|---|---|
| (Waiting for update.) | |
FDA labeling changes(Total Drugs:0) | |
|---|---|
| (Waiting for update.) | |